Cancer information / Cancer 101 / Cancer research / Radiation therapy

Aluwini S, Pos F, Schimmel E et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. (2015, February). Lancet Oncology. 16(3):274-283.

Blumenthal DT, Rankin C, Stelzer KJ et al. A phase III study of radiation therapy (RT) and O6-benzylguanine, (O6-BG) plus BCNU versus RT and BCNU alone and methylation status in newly-diagnosed glioblastoma (GBM) and gliosarcoma: Southwest Oncology Group (SWOG) Study S0001. (2015, August). International Journal of Clinical Oncology. 20(4):650-658.

Brundage M, Sydes MR, Parulekar WR et al. Impact of radiotherapy when added to androgen-deprivation therapy for locally advanced prostate cancer: long-term quality-of-life outcomes from the NCIC CTG PR3/MRC PR07 randomized trial. (2015, July 1). Journal of Clinical Oncology. 33(19):2154-2157.

Budach V, Stromberger C, Poettgen C et al. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. (2015, February). International Journal of Radiation Oncology, Biology, Physics. 91(5):916-924.

Faivre-Finn C, Falk S, Ashcroft L et al. Protocol for the CONVERT trial— Concurrent ONce-daily VErsus twice daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. (2016). BMJ Open. 6(1):1-7.

Ghia AJ, Chang EL, Bishop AJ et al. Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma: secondary analysis of Phase I/II trials. (2016). Journal of Neurosurgery: Spine. 24:829-836.

Giaddui T, Chen W, Yu J et al. Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage IIIIIB NSCLC. (2016). Radiation Oncology. 11:66-73.

Harrington K, Temam S, Mehanna H et al. Postoperative adjuvant lapatinib and concurrent chemoradiotherapy followed by maintenance lapatinib monotherapy in high-risk patients with resected squamous cell carcinoma of the head and neck: a phase III, randomized, double-blind, placebo-controlled study. (2015, December 10). Journal of Clinical Oncology. 33(35):4202-4209.

Hassan Metwally MA, Ali R, Kuddu M, Shouman T, Strojan P, Iqbal K, et al. IAEA-HypoX: a randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma. (2015). Radiotherapy and Oncology. 16(1):15-20.

Hoskin P, Rojas A, Fidarova E et al. IAEA randomized trial of optimal single dose radiotherapy in the treatment of painful bone metastases. (2015). Radiotherapy and Oncology. 116:10-14.

Karakhanova S, Ryschich E, Mosl B et al. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. (2015). BJC. 112:1027-1036.

Kim R, Prithviraj GK, Shridhar R et al. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. (2016). Radiotherapy and Oncology. 118:382-386.

Kokabi N, Camacho JC, Xing M et al. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. (2015, July 1). Cancer. 121(13): 2164-2174.

Roa W, Kepka L, Kumar N et al. International atomic energy agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. (2015). Journal of Clinical Oncology. 33(35):4145-4150.

Sharma M, Revannasiddaiah S, Gupta M et al. Can pure accelerated radiotherapy given as six fractions weekly be an option in locally advanced carcinoma cervix: Results of a prospective randomized phase III trial. (2016). Journal of Cancer Research and Therapeutics. 12(1):103-108.

Songthong AP, Kannarunimit D, Chakkabat C et al. A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events. (2015). Radiation Oncology. 10:166-176.

Wilkins A, Mossop H, Syndikus I et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. (2015, December). Lancet Oncology. 16:1605-1616.

Zackrisson B, Kjellen E, Soderstrom K et al. Mature results from a Swedish comparison study of conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma - The ARTSCAN trial. (2015). Radiotherapy and Oncology. 117:99-105.

Zhao Q, Wang Z, Huang W et al. Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer. (2016, January). Oncotarget. 7(7):8422-8431.